Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

101
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
101
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

96
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
96
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

138
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
138
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

126
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
126
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

147
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
147
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

113
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
113

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ironing Out the Details: Advancing Diagnosis and Treatment of Iron Deficiency in Patients with Heart Failure with Preserved Ejection Fraction - A Narrative Review.

Heart failure reviews·2026
Same author

At the Edge of the Possible: A New Standard for Cardiovascular Critical Care.

Cardiology clinics·2026
Same author

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026
Same author

Real-time cardiac power output index predicts imminent need for extracorporeal membrane oxygenation after heart transplantation.

JHLT open·2026
Same author

Associations Between Admission C-Reactive Protein and In-Hospital Mortality Amongst Patients with Cardiogenic Shock.

European heart journal. Acute cardiovascular care·2026
Same author

Phenotype-Guided Mechanical Circulatory Support in Cardiogenic Shock: Signal, Noise, or a Path to Precision Care?

Journal of cardiac failure·2026

Related Experiment Video

Updated: May 7, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.1K

Acute Decompensated Valvular Disease in the Intensive Care Unit.

P Elliott Miller1, Balimkiz C Senman2, Ann Gage3

  • 1Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

JACC. Advances
|December 30, 2024
PubMed
Summary

Acute decompensated valvular disease requires specialized care in cardiac intensive care units. This review addresses diagnostic and management challenges for critically ill patients with valvular disorders.

Keywords:
cardiac intensive care unitcardiogenic shockvalvular disease

More Related Videos

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

1.8K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.4K

Related Experiment Videos

Last Updated: May 7, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.1K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

1.8K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.4K

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Valvular Heart Disease

Background:

  • Acute decompensated valvular disease is a frequent cause for cardiac intensive care unit (CICU) admission.
  • Critically ill patients with valvular disease present unique diagnostic and management challenges.
  • Limited medical and percutaneous options historically left surgery as the sole definitive treatment, though surgical risk can be prohibitive.

Purpose of the Study:

  • To review the clinical presentation and epidemiology of valvular diseases in the CICU.
  • To highlight key pathophysiology and identify evidence gaps in managing acute valvular disorders.
  • To provide management guidance for critically ill patients with decompensated valvular disease.

Main Methods:

  • Literature review focusing on acute valvular disorders in critically ill patients.
  • Analysis of diagnostic and management strategies.
  • Emphasis on the role of multidisciplinary Heart Teams.

Main Results:

  • Lack of high-quality evidence and guideline recommendations for this specific patient population.
  • Identification of diagnostic and therapeutic challenges.
  • Recognition of the importance of a Heart Team approach.

Conclusions:

  • Management of acute decompensated valvular disease in critically ill patients is complex.
  • Multidisciplinary Heart Teams are crucial for optimal patient care.
  • Further research is needed to address evidence gaps and refine treatment strategies.